
Atty. Dkt. No. 029488-0113 U.S. Serial No. 10/734,638



## AMENDMENTS TO THE CLAIMS

This listing replaces all prior versions and listings of claims in the application.

## Listing of Claims

1-25. (Cancelled)

- 26. (Currently Amended) A pharmaceutical composition for percutaneous administration comprising 4-hydroxy tamoxifon a pharmaceutically active agent and at least one fatty acid ester penetration enhancer, wherein the pharmaceutically active agent consists essentially of 4-hydroxy tamoxifen.
- 27. (Previously Presented) A composition according to claim 26, wherein the pharmaceutical composition is a hydroalcoholic gel.
- 28. (Previously Presented) A composition according to claim 26, wherein the pharmaceutical composition comprises a penetration enhancer, an aqueous vehicle, an alcoholic vehicle and a gelling agent.

Claims 29-30 (Cancelled)

- 31. (Previously Presented) A composition according to claim 28, wherein the pharmaceutical composition comprises: a) about 0.001% to 1.0 % by weight of 4-hydroxy tamoxifen, b) about 0.5% to 2% by weight of isopropyl myristate, c) about 65% to 75% by weight of alcohol, d) about 20% to 35% by weight of aqueous vehicle, e) about 1.0% to 5% by weight of gelling agent, wherein the percentage of components are weight to weight of the composition.
- 32. (Original) A composition according to claim 31, wherein the 4-hydroxy tamoxifen constitutes about 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, or 0.10% by weight of the composition.